



**CORPORATE ACTION NOTICE  
TERMINATION NOTICE**

**\*\*\*UPDATE\*\*\***

September 8, 2025

**NOTICE TO HOLDERS OF GLOBAL DEPOSITARY RECEIPTS ("GDRs")  
REPRESENTING DEPOSITED ORDINARY SHARES OF:  
STERLING BIOTECH LIMITED - REG S  
ONE GDR REPRESENTS SIX ORDINARY SHARES  
CUSIP: 85916G108 AND UNDERLYING ISIN: INE324C01038**

As owners and beneficial owners of the above GDRs (the "Holders"), you were notified by The Bank of New York Mellon, as depositary (the "Depositary"), on December 5, 2016, that the Deposit Agreement, dated October 1, 2003, between Sterling Biotech Limited ("Sterling Biotech") the Depositary, and the Holders (the "Deposit Agreement") was terminated on March 6, 2017.

As an update, the Depositary has been notified that an order issued by the National Company Law Tribunal, Court Room No 1, Mumbai Bench, Item No. 20 (the "Order"), dated July 29, 2025, has directed the local Central Securities Depositories, National Securities Depository Limited and Central Depository Services (India) Limited, to: (a) take note of a November 11, 2022 Order extinguishing and cancelling the existing ordinary shares of Sterling Biotech and (b) cancel ISIN: INE324C01038, and (c) to the extent not already accomplished, cancel and extinguish any existing ordinary shares of Sterling Biotech, within 30 days from the date of communication of this Order.

As a result, all ordinary shares underlying the GDRs were removed from our custodian's account around August 26, 2025. The Depositary will not be able to deliver any of those ordinary shares upon surrender and cancellation of GDRs and will not be able to sell such ordinary shares or obtain any value to make a payment to GDR holders. The GDRs are deemed to be worthless.

The Depositary has permanently closed its books as of the date hereof. No further action is required by a GDR holder.

**PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.**

For Settlement specific inquiries, please contact [DRsettlements@bnymellon.com](mailto:DRsettlements@bnymellon.com)

## Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY. In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary. In such cases, BNY has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed at [https://www.adrbny.com/content/dam/adr/documents/fees-and-disclosures-pdf/drs\\_foreign\\_exchange\\_pricing\\_disclosure.pdf](https://www.adrbny.com/content/dam/adr/documents/fees-and-disclosures-pdf/drs_foreign_exchange_pricing_disclosure.pdf).

In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or to ensure that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency. In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is the most favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY.

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

**DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED**

# Corporate Action Notice

## Termination Notice

December 5, 2016

### NOTICE TO HOLDERS OF GLOBAL DEPOSITARY SHARES EVIDENCED BY GLOBAL DEPOSITARY RECEIPTS

#### REPRESENTING DEPOSITED ORDINARY SHARES OF:

#### **Sterling Biotech Limited**

ONE GDS REPRESENTS SIX SHARES

Reg S CUSIP: 85916G108

You are hereby notified as owners and beneficial owners of the above Global Depositary Receipts ("GDRs"), that we will terminate the Deposit Agreement, dated October 1, 2003, between Sterling Biotech Limited ("Sterling Biotech") and The Bank of New York Mellon, as Depositary (the "Deposit Agreement"). As a result, the existing GDR facility will be terminated effective 5:00 pm (Eastern Time) on **March 6, 2017**.

As a result of the termination of the Deposit Agreement described above, you have until at least **March 7, 2017** to decide if you would like to retain your interest in shares of the Issuer. If you do not surrender your GDRs and request delivery of the underlying shares before the Depositary sells those shares, you will lose the right to receive those shares and instead will be entitled, upon subsequent surrender of your GDRs, to receive the net proceeds of sale of those shares net of surrender fees of up to \$0.05 per GDR surrendered. The date or dates on which the Depositary will sell remaining deposited shares has not been determined, but it will not be earlier than **March 7, 2017**.

**Please be aware that it is the Depositary's understanding that this intended sale by the Depositary of the deposited shares, as and when the sale occurs, referred to above will be subject to Indian withholding tax at the maximum rate currently at 43.26% of the gross proceeds. No tax reclamation process with the Income Tax Authorities of India for the aforementioned withholding tax will be provided by BNY Mellon.**

If you surrender GDRs with the intention of withdrawing the underlying shares before the depositary attempts to sell those shares, you must pay the fee of the Depositary as provided in the Deposit Agreement of up to \$0.05 per GDR surrendered, a cable fee of \$17.50 and any applicable taxes or governmental charges. Payment should be made payable to The Bank of New York Mellon. The address of the Depositary is: The Bank of New York Mellon, 101 Barclay Street, Depositary Receipts Division, 15th Floor, Attention: Cancellation Desk, New York, NY 10286. Registered or overnight mail is the suggested method of delivering GDRs to the Depositary.

If you wish to receive payment of the proceeds of sale of Issuer shares, please do not surrender your GDRs at this time. The Depositary will send a separate notice with instructions to surrender your GDRs after the sale of shares has been completed.

Terms used in this Notice and not otherwise defined therein shall have the meanings set forth in the Deposit Agreement. For further information regarding your GDRs, please contact the Depositary on telephone number 1-888-BNY-ADRS (1-888-269-2377).

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

#### **New York**

Ravi Davis

Richard J Maehr

+ 1 212 815 2267

adrdesk@bnymellon.com

#### **London**

Jacek Jankowski

DR Broker Liaison Support

+ 44 207 163 7427

jacek.jankowski@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliates and dealers. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities. The conversion rate reflects a foreign currency ("FX") transaction ("FX Trade") executed by BNY Mellon as principal counterparty and not as agent, fiduciary or broker. BNY Mellon has no obligation to obtain the "best price" for any FX Trade. BNY Mellon earns revenue on the FX Trade based on, among other things, the difference between the rate it assigns to the FX Trade and the rate that it pays and receives for purchases and sales of currencies when engaging in any offsetting trades for its own account. The decisions BNY Mellon makes on when and how to enter into any offsetting trades, as well as other factors (including but not limited to liquidity and market volatility), affect the revenue BNY Mellon earns on FX Trades.



**BNY MELLON**